About Boule Diagnostics

Boule Diagnostics AB (publ) is a global diagnostics company specializing in near-patient, decentralized blood diagnostics and one of the few companies in the global diagnostics market that conducts its own development, manufacturing and marketing of instruments and consumables for blood diagnostics. The Company primarily serves hospitals, clinics, laboratories and other diagnostics companies to which it offers complete systems for blood diagnostics (hematology) in both the human and veterinary areas. Boule has strong positions in important emerging markets such as in Asia and in recent years has improved its position in the fast-growing veterinary market. Operations are conducted through operating subsidiaries in Sweden, the United States, Mexico and Russia. The Group reported net sales of approximately SEK 400 million in 2020 and has over 200 employees. Sales are conducted globally, predominantly through the company's 200 or so distributors in over 100 countries, supported by Boule's own local sales and service personnel. Boule has been listed on Nasdaq Stockholm since 2011.

Calendar

Other information

Calendar

Interim report Q1 2022	May 4, 2022
2022 Annual General Meeting	May 5, 2022
Interim report Q2 2022	July 18, 2022
Interim report Q3 2022	November 10, 2022

Presentation and conference

Presentation of the interim report
CEO Jesper Söderqvist and CFO Christina Rubenhag will present and comment on the interim report through Teams. After the presentation, there will be time for questions.

The presentation will be held in English.

Time: 09.00, February 3, 2022

Please follow this link to participate.

Contact persons

Jesper Söderqvist
President and CEO
+46 (0)70-689 05 90
jesper.soderqvist@boule.com

Christina Rubenhag
CFO
+46 (0)70-546 72 22
christina.rubenhag@boule.com

This information is information that Boule Diagnostics AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:30 CET on February 3, 2022.